<SEC-DOCUMENT>0001213900-20-010944.txt : 20200505
<SEC-HEADER>0001213900-20-010944.hdr.sgml : 20200505
<ACCEPTANCE-DATETIME>20200505061037
ACCESSION NUMBER:		0001213900-20-010944
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200430
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200505
DATE AS OF CHANGE:		20200505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SG BLOCKS, INC.
		CENTRAL INDEX KEY:			0001023994
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-LUMBER & OTHER CONSTRUCTION MATERIALS [5030]
		IRS NUMBER:				954463937
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38037
		FILM NUMBER:		20846726

	BUSINESS ADDRESS:	
		STREET 1:		195 MONTAGUE STREET, 14TH FLOOR
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11201
		BUSINESS PHONE:		(646) 240-4235

	MAIL ADDRESS:	
		STREET 1:		195 MONTAGUE STREET, 14TH FLOOR
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CDSI HOLDINGS INC
		DATE OF NAME CHANGE:	19990114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PC411 INC
		DATE OF NAME CHANGE:	19961001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea121379-8k_sgblocksinc.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
<B>April 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SG BLOCKS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-38037</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>95-4463937</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction<BR>
of Incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>195 Montague Street, 14th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Brooklyn, NY 11201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices,
Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: 646-240-4235</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of Each Class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Each Exchange on Which Registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock, par value $0.01</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SGBX</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01.&nbsp;&nbsp;Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30,
2020, SG Blocks, Inc. (the &ldquo;Company&rdquo;) entered into a Distributorship Agreement (the &ldquo;Distributorship
Agreement&rdquo;) with Osang Healthcare Co., Ltd., a Republic of Korea company (&ldquo;Osang&rdquo;), effective as of April
28, 2020, for its GeneFinder&trade; COVID-19 Plus RealAmp Kit&trade;, designed to detect SARS-CoV-2 (<I>Severe Acute
Respiratory Syndrome-Coronavirus 2</I>), the virus that causes COVID-19, through a gene-based reverse transcription reaction
and real-time polymerase chain reaction (PCR) testing process. The Distributorship Agreement is Osang&rsquo;s standard form
and provides the Company with the non-exclusive right to distribute Osang&rsquo;s GeneFinder COVID-19 Plus RealAmp Kit in the
United States for a stated term of one (1) year. The Distributorship Agreement does not guarantee the Company a specific
quantity of kits to sell or a customer list, and may be terminated by either party at any time on thirty (30) days&rsquo;
notice. Pursuant to the terms of the Distributorship Agreement, the Company is required to make payment for 100% of any
purchase order prior to shipment of the product from Osang, though it does not expect to make any cash outlays with respect
to any product that it distributes and expects instead to require any third-party purchasers to make the necessary cash
outlays as part of a purchase order entered into with the Company. On April 30, 2020, the Distributorship Agreement was
amended (the &ldquo;Amendment&rdquo;) to provide the Company with certain additional warranties from Osang.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 1, 2020, in connection
with the entry into the Distributorship Agreement, the Company entered into an agreement with an affiliate of Osang (the &ldquo;ROP&rdquo;)
granting it the right to participate in up to 19.9% of any offering effected by the Company during the next six (6) months provided
that Osang or its affiliates provides customer referrals to the Company for the purchase under the Distributorship Agreement of
kits resulting in at least $5 million of revenues to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the Distributorship Agreement will continue, that it will yield the anticipated benefits or generate significant revenue,
if any. To date, the Company has never sold any medical devices or kits and there can be no guarantee that the Company will be
able to establish distribution channels or solicit customers for the kits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
of the terms of the Distributorship Agreement, the Amendment and the ROP do not purport to be complete and are subject to, and
are qualified in their entirety by, reference to the provisions of such agreements, which are filed as Exhibits 10.1, 10.2 and
10.3 to this Current Report on Form 8-K and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2020, the
Company issued a press release announcing that it had entered into a Distributorship Agreement with Osang for its GeneFinder&trade;
COVID-19 Plus RealAmp Kit test for SARS-CoV-2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press
release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished
to the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and shall not be deemed incorporated by reference into
any of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Updating Risk Factors </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is including
the risk factors below for the purpose of supplementing and updating the risk factor disclosure contained in Part I&ndash;Item
1A&ndash;Risk Factors in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2019 (&ldquo;Annual
Report on Form 10-K&rdquo;), filed with the Commission on March 30, 2020. The following risk factors should be read in conjunction
with the risk factors described in the Company&rsquo;s Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There can be no assurance that the
Distributorship Agreement with Osang will generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 30, 2020, the
Company entered into the Distributorship Agreement with Osang that provides the Company with the non-exclusive right to distribute
Osang&rsquo;s GeneFinder COVID-19 Plus RealAmp Kit in the United States for a stated term of one (1) year. The Distribution Agreement
does not guarantee the Company a specific quantity of kits to sell or a customer list, requires the Company to pay for 100% of
the purchase order prior to delivery (though the Company does not expect to make any cash outlays for product and expects instead
to require the Company&rsquo;s customers to make such cash outlays) and may be terminated by either party at any time on thirty
(30) days&rsquo; notice. To date, the Company has never sold any medical devices or kits and there can be no guarantee that it
will be able to establish a sales force, establish distribution channels or solicit customers for the kits. There can be no assurance
that the Distributorship Agreement will continue, that it will yield the anticipated benefits or generate significant revenue,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify"><B><I>Product liability and other
claims with respect to Osang&rsquo;s GeneFinder COVID-19 Plus RealAmp Kit may have material adverse effects on the Company&rsquo;s
business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Companies that distribute
medical tests, are generally subject to risks related to product liability litigation and other claims or litigation. Product liability
risks are inherent in marketing and sale of pharmaceutical products. Even though the Company is not currently subject to any product
liability claims, such claims could arise at a later date. Though Osang has agreed to indemnify the Company for certain
product liability claims, claims arising under the Distributorship Agreement must be arbitrated in Singapore and enforcement of
such indemnification provisions would be time-consuming for the Company&rsquo;s management
and lead to significant costs and losses, which would adversely affect its business, results of operations, cash flows, financial
condition, and/or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even though the
Company intends to obtain product liability insurance and Osang has agreed to indemnify the Company for certain claims
arising from the manufacture of the kits, there can be no assurance that such insurance coverage will continue to be
available on reasonable commercial terms or that such insurance or indemnification will prove adequate. If sufficient insurance coverage is not obtained
covering product liability, or if such future litigation or investigation exceeds the Company&rsquo;s insurance coverage, the Company could
be subject to significant liabilities, which could have material adverse effect on its business, results of operations, cash
flows, financial condition, and/or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01.&nbsp;&nbsp;Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><I>Exhibits</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 91%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Exhibit</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea121379ex10-1_sgblocksinc.htm">Distributorship Agreement between Osang Healthcare Co., Ltd. and SG Blocks, Inc., effective as of April 28, 2020</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea121379ex10-2_sgblocksinc.htm">Amendment to Distributorship Agreement between Osang Healthcare Co., Ltd. and SG Blocks, Inc., dated April 30, 2020</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea121379ex10-3_sgblocksinc.htm">Agreement between Osang Group Co. Ltd. and SG Blocks, Inc., dated May 1, 2020</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea121379ex99-1_sgblocksinc.htm">SG Blocks, Inc. Press Release, dated May 5, 2020</A></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Confidential portions of this exhibit have been omitted
from the exhibit.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SG Blocks, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 5, 2020&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul Galvin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Galvin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea121379ex10-1_sgblocksinc.htm
<DESCRIPTION>DISTRIBUTORSHIP AGREEMENT BETWEEN OSANG HEALTHCARE CO., LTD. AND SG BLOCKS, INC., DATED APRIL 28, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PORTIONS HEREIN IDENTIFIED BY [*****]
HAVE BEEN EXCLUDED &nbsp;FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Confidential and Proprietary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Distributorship
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Distributorship
Agreement (&ldquo;<B>Agreement</B>&rdquo;) is made and entered into, effective as of April 28, 2020 (&ldquo;<B>Effective Date</B>&rdquo;), by and between OSANG Healthcare Co., Ltd. with its principal place of business
at 132, Anyangcheondong-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Republic of Korea (&ldquo;<B>Manufacturer</B>&rdquo;) and SG Blocks,
Inc. with its principal place of business at 195 Montague St., Brooklyn, NY 11201, United States of America (&ldquo;<B>Distributor</B>&rdquo;).
Manufacturer and Distributor are sometimes referred to individually as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 257.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Manufacturer
and Distributor have discussed the terms and conditions of transactions regarding certain products hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE,
</B>in consideration of the mutual promises and covenants set forth herein, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 1</B>. Manufacturer
agrees to sell and deliver to Distributor and Distributor agrees to purchase and distribute the following products (&ldquo;<B>Product</B>&rdquo;)
from Manufacturer under this Agreement during the Term (as defined in Article 3). For any Manufacturer&rsquo;s products (in-vitro
glucose, HbA1c, cholesterol, immunoassay and/or molecular diagnostic tests, instruments, accessories, etc.) other than the Product,
Manufacturer and Distributor may discuss and negotiate the terms and conditions therefor as separate agreements. The unit price
of the Product below may be changed upon Manufacturer&rsquo;s written notice to Distributor in accordance with any price changes
on raw materials required for manufacture of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product (Ref. No. IMFR-45)</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Price Per Test (1Kit = 100 Test)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">GeneFinder COVID-19 Plus Real<I>Amp </I>Kit</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">USD $[*****]/Test</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Plus any applicable freight charges</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 2. </B>Manufacturer
grants to Distributor the non-exclusive rights to purchase, import, promote, market, sell, distribute and perform after-sales services
for the Products within the geographic area of the United States of America (&ldquo;<B>Territory</B>&rdquo;). In connection with
the foregoing rights granted to Distributor, Distributor agrees and acknowledges that the Product shall be used only with Applied
Biosystem 7500/7500 Fast Real-time PCR System and Bio-Rad CFX96 Real-time PCR Detection System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 3.</B> This
Agreement shall take effect on the Effective Date and end on April 28, 2021 (&ldquo;<B>Term</B>&rdquo;) unless earlier terminated
at any time by either Party giving the other at least thirty (30) days prior written notice. The Term may be extended by a written
instrument executed by duly authorized representatives if the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 4.</B> Distributor
shall place a purchase order for the Products to manufacturer in writing and Manufacturer will use commercially reasonable efforts
to deliver Products within two (2) weeks from the date Manufacturer received and accepted the purchase order from Distributor.
For each purchase order over 5,000 Kits, however, Manufacturer will deliver the Product after it discusses any possible delivery
date with Distributor. The Products will be packed in a special dry-iced package. The delivery of Product shall be made according
to EXW Manufacturer&rsquo;s facility (EX Works Incoterms 2010). Distributor shall pay 100% of purchase order amount subsequent
to receipt of an invoice for each respective order and before shipment of the Products by means of telegraphic transfer (T/T).
All payments shall be made in USD (United States Dollar).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Confidential and Proprietary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 5.</B> Manufacturer
warrants and covenants that all of the Products shall be free from defects in materials and workmanship. The warranty for the Products
shall be effective during each shelf life of the Products. Notwithstanding the foregoing, Manufacturer&rsquo;s warranty shall not
extend to any of the Products which have been (i) misused or abused, (ii) improperly repaired, altered or modified, (iii) used
in violation of Manufacturer&rsquo;s instruction, or (iv) damaged during transportation or demonstration unless otherwise specified
in any relevant warranty conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 6. </B>Distributor
agrees that Manufacturer is the exclusive owner of all confidential information provided by Manufacturer. Distributor shall not
directly or indirectly disclose the confidential information to any person or entity and will take necessary precautions to prevent
any such disclosure by any of its employees or agents. The confidentiality obligations of this Agreement will survive the termination
of expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 7.</B> Distributor
shall indemnify and hold harmless Manufacturer and its respective directors, officers, agents and employees from and against any
and all liabilities, claims, suits, losses, damages or causes of actions including costs, attorney fees and expenses which may
be suffered by any loss, damage, death or bodily injury arising out of (i) Distributor&rsquo;s negligent acts in connection with
the use, sales or after-sale service of the Products, or (ii) Distributor&rsquo;s breach of obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 8.</B> This
Agreement constitutes the entire agreement of the Parties on the subject matter hereof and supersedes all prior understandings
and instruments on such subject matter. This Agreement may not be modified other than by a written instrument executed by duly
authorized representatives of the Parties. For purposes of this Agreement, signatures transmitted in a facsimile machine or in
a document attached to an email shall be deemed to be original signatures. In addition, if any of the Parties sign facsimile or
emailed copies of this Agreement, such copies shall be deemed originals. This Agreement may be executed in two or more counterparts,
all of which shall be considered one and the same agreement, it being understood that all Parties need not sign the same counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Article 9.</B> This
Agreement shall be construed and enforced according to the laws of Republic of Korea without application of its conflicts of laws
principals. All disputes arising out of this Agreement shall be finally settled by arbitration in Singapore with the English language
under the Arbitration Rules of Singapore International Arbitration Centre.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The Signature Page Follows on the Next
Page</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Confidential and Proprietary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Parties have
executed this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For and on behalf of Manufacturer:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For and on behalf of Distributor:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>OSANG Healthcare Co., Ltd.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SG Blocks, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">s/ Dong-Hyun Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">s/ Paul M. Galvin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Print Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dong-Hyun Lee</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Print Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paul M. Galvin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1.5pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea121379ex10-2_sgblocksinc.htm
<DESCRIPTION>AMENDMENT TO DISTRIBUTORSHIP AGREEMENT BETWEEN OSANG HEALTHCARE CO., LTD. AND SG BLOCKS, INC., DATED APRIL 30, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDMENT TO DISTRIBUTORSHIP AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
<B>AMENDMENT </B>(the &ldquo;<B><I>Amendment</I></B>&rdquo;) is made and entered into as of the 30<SUP>th</SUP> day of April, 2020,
to the <B>DISTRIBUTORSHIP AGREEMENT</B>, dated as of April 28, 2020 (the &ldquo;<B><I>Distributorship Agreement</I></B>&rdquo;),
by and between Osang Healthcare Co., Ltd. (the &ldquo;<B><I>Manufacturer</I></B>&rdquo;)</FONT> and SG Blocks,, Inc. (the &ldquo;<B><I>Distributor</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B>, in consideration of </FONT>the mutual covenants and agreements contained in the Distributorship Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The
Distributorship Agreement is hereby amended by the inclusion therein of the representations and indemnities set forth on <U>Annex
A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. All
other terms of the Distributorship Agreement shall remain in full force and effect. The Distributorship Agreement, as amended by
this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.
This Amendment may be executed in two or more identical counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party;
provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with
the same force and effect as if the signature were an original, not a facsimile signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B> the parties have
executed this Amendment to the Distributorship Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OSANG HEALTHCARE CO., LTD.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SG BLOCKS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dong-Hyin Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul Galvin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dong-Hyin Lee</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Galvin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>ANNEX A</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturer warrants and covenants that:
(a) the Products will conform to their published specifications; (b) it owns all right, title, and interest in the Products and
in all of patents, trademarks, trade names, inventions, copyrights, know-how, and trade secrets relating to the design, manufacture,
operation, or service of the Products and (c) to its knowledge, the Products do not infringe any third party rights and will not
subject Distributor to liability for violation of any laws, rules or regulations. Defective Products may be returned by Distributor
to Manufacturer within 90 days of delivery and shall be promptly replaced by Manufacturer without charge and shipped to Distributor
at Manufacturer&rsquo;s expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturer shall indemnify and hold harmless
Distributor and its respective directors, officers, agents and employees from and against any and all liabilities, claims, suits,
losses, damages or causes of actions including costs, attorney fees and expenses which may be suffered by any loss, damage, death
or bodily injury (collectively the &ldquo;Liability&rdquo;) directly and proximately caused by a breach of the representations
or warranties contained in the Agreement (as amended), claims made by any person or entity arising out of the manufacturing of
the Products, claims asserting that a Product infringes the intellectual property of any other person or entity; or that use of
the Products resulted in bodily injury, without limitation, personal injury and death or the non-performance or improper performance
by Manufacturer of any of its obligations arising out of or in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea121379ex10-3_sgblocksinc.htm
<DESCRIPTION>AGREEMENT BETWEEN OSANG GROUP CO. LTD. AND SG BLOCKS, INC., DATED MAY 1, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 1, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA ELECTRONIC MAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Osang Group Co Ltd.<BR>
132, Anyangcheondong-ro Dongan -gu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anyang -si, Gye onggi do, 14040</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Republic of Korea<BR>
Attention: DH Lee, President and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B><I>Re:</I></B></TD><TD STYLE="text-align: justify"><B><I><U>Right of Participation in Future Financing</U></I></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Lee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reference is made to
that certain Distributorship Agreement between you and us of even date herewith (the &ldquo;Distributorship Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that you
provide customer referrals to us for the purchase under the Distributorship Agreement of Products (as defined therein) resulting
in at least $5,000,000 of revenue to us, we agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Subject
to the prior approval of The Nasdaq Stock Market and subject to any other rights of participation outstanding on the date hereof
this Agreement, until the six month anniversary of the date of this Agreement, upon any issuance by us of shares of our common
stock, and provided that such securities remain outstanding after the exercise of participation rights outstanding on the date
of this Agreement (herein, a &ldquo;Subsequent Financing&rdquo;), you shall have the right to participate in up to an amount of
the Subsequent Financing equal to 19.9% of the Subsequent Financing (the &ldquo;Participation Maximum&rdquo;) on the same terms,
conditions and price provided for in the Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) At the
time we commence soliciting interest of investors in the Subsequent Financing we will provide you notice of the potential Subsequent
Financing, and no less than two hours prior to pricing of any such Subsequent Financing we will deliver to you a written notice
of our intention to effect a Subsequent Financing (a &ldquo;Subsequent Financing Notice&rdquo;), which notice shall describe in
reasonable detail the proposed terms of such Subsequent Financing and the amount of proceeds intended to be raised thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) In the
event you desire to participate in such Subsequent Financing you must provide written notice to us within one hour of being provided
the terms of the Subsequent Financing (the &ldquo;Notice Termination Time&rdquo;) that you are willing to participate in the Subsequent
Financing, the amount of your participation, and representing and warranting that you have such funds ready, willing, and available
for investment on the terms set forth in the Subsequent Financing Notice, in order to ensure we have adequate time to include your
investment in the Subsequent Financing. If we receive no such notice from you as of such Notice Termination Time, you will be deemed
to have notified us that you do not elect to participate in such Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 119.35pt 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 119.35pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 119.35pt 0pt 0"><B>SG Blocks, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 119.35pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul M. Galvin</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul M. Galvin</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">195 Montague Street, 14th Floor Brooklyn
Heights, NY 11201 646.240.4235 P info@sgblocks.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nashville&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New
York&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charleston</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ea121379ex99-1_sgblocksinc.htm
<DESCRIPTION>SG BLOCKS, INC. PRESS RELEASE, DATED MAY 5, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 12.9pt 0 59pt; text-indent: -45.05pt"><FONT STYLE="font-size: 18pt"><B>SG
Blocks Signs Agreement with OSANG Healthcare to Distribute COVID-19 Rapid Tests in U.S. under OSANG&rsquo;s FDA Emergency Use
Authorization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 13.65pt 0 45.65pt; text-indent: -31.2pt"><FONT STYLE="font-size: 16pt">Complements
SGB&rsquo;s recent announcement of its strategic drive into medical &lsquo;pop up&rsquo; clinics and testing centers using its
custom modular solutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">BROOKLYN, N.Y.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/ May 5, 2020/ SG Blocks, Inc. (Nasdaq: SGBX)
(&ldquo;SG Blocks&rdquo; or the &ldquo;Company&rdquo;), a leading designer, innovator and fabricator of container-based structures,
and OSANG Healthcare Co., Ltd. (&ldquo;OHC&rdquo;), a South Korea based global manufacturer and distributor of medical-grade diagnostic
tests and equipment, announced today the signing of a one year, non-exclusive distributorship agreement for the United States,
for OHC&rsquo;s &ldquo;GeneFinder&reg; COVID-19 Plus RealAmp Kit&rdquo; &ndash; a simple SARS-CoV-2 test for COVID-19, now available
in the United States under the FDA&rsquo;s Emergency Use Authorization (EUA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify">OHC&rsquo;s &ldquo;GeneFinder<SUP>&reg;</SUP>
COVID-19 Plus Real<I>Amp </I>Kit&rdquo; test is designed to detect SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2),
the virus that causes COVID-19, through a gene-based reverse transcription reaction and real-time polymerase chain reaction (PCR)
testing process that can provide up to 100 tests results in just over two hours, making them ideally suited to emergency, pop-
up and point of care situations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">SG Blocks will have sales, marketing
and distribution rights to OHC&rsquo;s product in the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.95pt; text-align: justify">United States and plans to leverage
its customer base and relationships with federal government and state-level customers in particular who are only beginning to roll-out
widespread SARS-CoV-2 testing centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.95pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.95pt; text-align: justify">Paul Galvin, CEO of SG Blocks
commented, &ldquo;We believe that this agreement will enable SG Blocks to create turnkey testing facilities at hospitals and other
authorized point of care medical locations throughout the USA, including buildings that SG Blocks plans to provide to customers
using our modular construction expertise. OHC&rsquo;s SARS-CoV-2 test was used by leading emergency services and front-line hospitals
during the height of the COVID-19 epidemic in Europe and is now finding favor and rapid acceptance in the USA Its ease-of-use,
accuracy and ability to work on low-cost point-of-care analyzers should make it ideally suited to our portable module solutions.
As we strive to return to normal life, it is critical to free up hospitals to perform normal duties again. We believe that our
units, once developed, can help provide safe, isolated SARS-CoV-2 testing and &lsquo;lab-in-a-box&rsquo; solutions for these service
providers&ldquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">Dong-Hyun Lee, Chairman &amp;
Chief Executive Officer of OSANG Healthcare Co., Ltd. stated, &ldquo;We view SG Blocks as an ideal partner to broaden distribution
of our advanced tests and expand our ability to directly address this global pandemic in the USA. Our pipeline is substantial,
and SG Blocks has the ability to address logistical challenges utilizing their modular construction expertise.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in">In connection with the entry into the distributorship
agreement, subject to conditions the Company granted an affiliate of OHC the right to elect to participate, at its sole and exclusive
option, in up to 19.9% of any stock offering by the Company during the next six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in">ThinkEquity, a division of Fordham Financial Management,
Inc., acted as an advisor to SG Blocks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 18.1pt 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">About OSANG Healthcare Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">OSANG Healthcare is a South Korea
based global manufacturer and distributor of medical devices and in-vitro diagnostics solutions. Devoted since inception to the
development of diagnostic biosensors for blood glucose measurement, OSANG Healthcare envisions medical devices becoming as commonplace
as home appliances, easily measuring all diseases across the globe as &ldquo;Technology for Human&rdquo;. OSANG Healthcare currently
exports its diagnostic biosensors for blood glucose, HbA1c and cholesterol to more than 110 countries, in its drive to become the
leading researcher and developer of diagnostic sensors for heart disease and cancer, and of remote diagnosis systems. For more
information, visit <B><U>www.osanghc.com</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">About SG Blocks, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 6pt; text-align: justify">SG Blocks, Inc. is a premier innovator
in advancing and promoting the use of code- engineered cargo shipping containers for safe and sustainable construction. The firm
offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and
owners in achieving greener construction, faster execution, and stronger buildings of higher value. Each project starts with GreenSteel&trade;,
the structural core and shell of an SG Blocks building, and then customized to client specifications. For more information, visit
<B><U>www.sgblocks.com</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">Safe Harbor Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify">Certain statements in this press
release constitute &quot;forward-looking statements&quot; within the meaning of the federal securities laws. Words such as &quot;may,&quot;
&quot;might,&quot; &quot;will,&quot; &quot;should,&quot; &quot;believe,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;estimate,&quot;
&quot;continue,&quot; &quot;predict,&quot; &quot;forecast,&quot; &quot;project,&quot; &quot;plan,&quot; &quot;intend&quot; or similar
expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and include statements regarding plans to leverage our customer base
and relationships with federal and state-level customers, creating turnkey testing facilities at hospitals and other authorized
point of care medical locations throughout the USA, including buildings provided by SG Blocks and OHC&rsquo;s SARS-CoV-2 test being
ideally suited to the Company&rsquo;s portable module solutions, the Company&rsquo;s units, once developed, providing safe, isolated
SARS-CoV-2 testing and &lsquo;lab-in-a-box&rsquo; solutions. While SG Blocks believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the
date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult
to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth
or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current
expectations include, among others, our ability to leverage our customer base and relationships with federal and state-level customers
and use our modular construction expertise to create turnkey testing facilities at hospitals and other authorized point of care
medical locations throughout the USA, our ability to position SG Blocks for future profitability, our ability to maintain compliance
with the NASDAQ listing requirements, and the other factors discussed in the Company&rsquo;s Annual Report on Form 10-K for the
year ended December 31, 2019 and the Company&rsquo;s subsequent filings with the SEC, including subsequent periodic reports on
Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All product names used herein are trademarks of their respective
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><I>Media</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 322.9pt 0 6pt">Rubenstein Public Relations Christina Levin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 385.15pt 0 6pt">Account Director 212-805-3029</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><U>clevin@rubensteinpr.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 377.9pt 0 5.95pt; text-align: left"><I>Investor Relations </I>James
Carbonara Hayden IR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">(646) 755-7412</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><U>james@haydenir.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 414.95pt 0 6pt">Brett Maas Hayden IR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">(646) 536-7331</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><U>brett@haydenir.com</U>&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex10-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !L ,$# 2(  A$! Q$!_\0
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M\&/^"6W[9/QHDM]0F\ 2?#C0KPQR/XB^)VI_V9((9B#Y]OH"^?K$[;3O5&2
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MQ8TN-I)+?PIXYMXO"7BDP_>6&+5H1<:-=S;?E5Y!:%VP>IKZ \9?\%JOB/\
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M$+;<JSR)N7!8 'B/PG^TSXFMXH_[?T;2_%$0^]/9S_V=>;.%=W: F%Y .J.
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2Z\\UTU% "8'O^9_QHI:* /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
